Trabeculectomy with adjunctive intravitreal injection of bevacizumab (avastin). A preliminary study.

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-08000712

Enrollment

Unknown

Registered

2008-02-15

Start date

2008-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

1:Trabeculectomy with intravitreal injection of Bevacizumab (Avastin) for 30 to 60 min

Eligibility

Sex/Gender

Male

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1. Age 18 years or above 2. Eyes that undergo trabeculectomy 3. Patient able and willing to give informed consent to needling with intra-vitreal injection of bevacizumab.

Exclusion criteria

Exclusion criteria: Exclusion criteria 1. Single functional eye 2. Pregnant patients 3. Patients refusing trabeculectomy or bevacizumab injection 4. Use of anticoagulants or antiplatelet therapy other than aspirin/NSAIDs within 14 days of surgery. 5. Presence of a nonhealing wound, ulcer, fracture, or any medical condition associated with bleeding

Design outcomes

Primary

Measure	Time frame
Intra-ocular pressure;	—

Secondary

Measure	Time frame
Number of IOP-lowering medications;Visual acuity;Corneal clarity and corneal endothelial cell count;Bleb morphology (with photographic record);Progression in glaucomatous optic neuropathy and v;Lens status;Any complications from surgery;	—

Countries

China

Contacts

Public ContactProf. Dennis SC Lam

dennislam_cu_res@cuhk.edu.hk+852 27623134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026